After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

Skyrizi finished atop the Rx and over-the-counter (OTC) pharma brand ad rankings in August, according to data released by iSpot.tv on Wednesday afternoon. Skyrizi generated an impressions share of ...

The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study. The Food and Drug Administration (FDA) has approved Skyrizi ® (risankizumab-rzaa) for the ...

MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative ...